Sign In
Buy CMND
$2.91
-0.0100 (-0.342%)
At Close: Jun 03, 2026
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
07:55am, Friday, 28'th Jun 2024
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
07:57am, Thursday, 20'th Jun 2024
Vancouver, Canada, June 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
07:44am, Tuesday, 11'th Jun 2024
Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
08:24am, Friday, 10'th May 2024
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Cle
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
07:46am, Tuesday, 07'th May 2024
Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and
Clearmind Applies to Cease Being a Reporting Issuer in Canada
04:15pm, Tuesday, 30'th Apr 2024
Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) ("Clearmind" or the “Company”), a clinical- stage biotech company focused on discov
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
07:49am, Wednesday, 17'th Apr 2024
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
07:17am, Wednesday, 10'th Apr 2024
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and
Clearmind Medicine CEO Issues Letter to Shareholders
08:07am, Tuesday, 09'th Apr 2024
Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage biotech company focused on discovery a
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
09:12am, Wednesday, 27'th Mar 2024
Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
07:55am, Tuesday, 19'th Mar 2024
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),
CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)
02:55pm, Wednesday, 13'th Mar 2024
Toronto, Ontario--(Newsfile Corp. - Le 13 mars/March 2024) - The common shares of Clearmind Medicine Inc. will be delisted from the CSE at market close, March 14, 2024. The common shares currently tra
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
08:14am, Wednesday, 13'th Mar 2024
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
07:30am, Wednesday, 13'th Mar 2024
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
07:58am, Tuesday, 27'th Feb 2024
New patent applications build upon Clearmind's broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0
